Glivec
Lilly and Novartis face legal challenges
June 25, 2015Medical Communications, Sales and Marketing Gleevec, Glivec, Novartis, cymbalta, imatinib, lilly, zyprexa
Judges in California have ruled that Lilly should face claims it failed to fully disclose the extent of post-withdrawal side …
Novartis cancer drug beating path to NHS
October 17, 2014Sales and Marketing GIST, Glivec, NHS, NICE, imatinib, uturn
NICE has issued final draft guidance recommending Novartis’s Glivec for up to three years in people who have had a …
NICE U-turn on cancer drug despite price increase
June 27, 2014Sales and Marketing Cancer, Glivec, NHS, Novartis, gists
UK pricing watchdog NICE has performed a U-turn on Glivec (imatinib) by issuing new draft guidance recommending the drug, despite …
Novartis reports healthy profit
April 25, 2014Sales and Marketing Afinitor, Gleevec, Glivec, Novartis, Q1, lilly
Multiple sclerosis drug Gilenya and cancer treatment Afinitor were among the biggest sellers for Novartis, as the Swiss company’s net …
Sales rise for Novartis
January 30, 2014Sales and Marketing Gleevec, Glivec, Novartis, gilenya, q4, sales
Multiple sclerosis drug Gilenya, with sales rising 62% year-on-year to $1.9 billion, was one of the stars of last year …
Double approval for Pfizer cancer drugs
September 6, 2012Sales and Marketing CML, Cancer, Glivec, Pfizer, axitinib, rcc
Two cancer drugs from Pfizer have been approved, one in Europe for kidney cancer and another in the US for …
Novartis’ Indian patent case delayed
August 23, 2012Sales and Marketing Glivec, MSF, Novartis, generics
Novartis’ court case against the Indian government has been put on hold until next month. The case was suppose to …
Ariad files new blood cancer drug with the FDA
July 31, 2012Research and Development, Sales and Marketing Ariad, CML, EMA, FDA, Glivec, blood cancer
Ariad has filed its investigational blood cancer drug ponatinib with the FDA and hopes for an accelerated review. The US …
Bayer cancer drug meets Phase III goal
April 3, 2012Research and Development, Sales and Marketing Bayer, Cancer, Glivec, Novartis, phase III, regorafenib
Bayer’s stomach cancer pill regorafenib has significantly improved progression free survival in late-stage patients. Results from the Phase III trial …
Novartis Indian patent battle nears conclusion
March 7, 2012Sales and Marketing Glivec, HIV, India, Novartis, patents
A long-running battle over the patent of cancer treatment Glivec in India is about to reach its dramatic climax.India’s Supreme …
Glivec cleared for longer use in GIST patients
February 28, 2012Sales and Marketing Europe, GIST, Gleevec, Glivec, Novartis
Glivec has gained EU approval for extended use after surgery for adults with KIT (CD117)-positive gastrointestinal stromal tumours (GIST).The drug …
NICE says yes to Tasigna for resistant disease
January 13, 2012Sales and Marketing BMS, Glivec, NICE, Novartis, Tasigna
NICE is recommending Novartis’ Tasigna for chronic myeloid leukaemia patients that can no longer use Glivec. In final guidance it …
NICE recommends two Novartis cancer treatments
December 6, 2011Sales and Marketing Glivec, Novartis, Sprycel, Tasigna
Two of Novartis’ cancer drugs have been recommended by NICE for the first line treatment of chronic myeloid leukaemia (CML) …
New discount persuades NICE to back Novartis’ Tasigna
August 18, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has recommended Novartis’ Tasigna for use in the NHS after the blood cancer drug’s manufacturer submitted a new patient …
‘Weak’ evidence leads to NICE no for three leukaemia drugs
May 6, 2011Sales and Marketing Glivec, NICE, Sprycel, Tasigna
NICE has not recommended three major drugs for the rare blood cancer chronic myeloid leukaemia. In draft guidance on treating …
Latest content
Five Facts about cardiovascular disease
